Free Trial Information
BioCentury | Nov 19, 2020
Finance

Syncona enters kidney disease space with gene therapy newco Purespring

...area, and Spanish start-up Ninevah Therapeutics S.L. is developing gene therapies for monogenic kidney disorders.Hollowood wil...
Read More
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

Catalent Inc. (NYSE:CTLT) said Manja Boerman will become president of cell and gene therapy, succeeding Pete Buzy, who will continue as chairman of the gene therapy business. Boerman was president of the biotech’s European biologics...
Read More
BioCentury | May 22, 2019
Company News

Management tracks: Gottlieb re-joining NEA; plus Seattle Genetics, Celsius and more

...a consultant and SAB member for the gene therapy company. Voyager said CMO Omar Khwaja wil...
Read More
BioCentury | Oct 31, 2016
Financial News

Financial tracks

...named David Spaight operating partner in its healthcare group. Spaight was chairman and CEO of WIL...
Read More
BioCentury | Sep 2, 2016
Politics & Policy

Holiday notice

...Monday, Sept. 5, in observance of the Labor Day holiday in the U.S. BioCentury Extra wil...
Read More
BioCentury | Jan 16, 2016
Politics & Policy

Holiday notice

...BioCentury Extra wil not publish Monday, Jan. 18, in observance of the Martin Luther King, Jr...
Read More
BioCentury | Jan 11, 2016
Analyst Picks & Changes

Finance

...raised his target range to $87-$90 from $78-$80 after Charles River said it will acquire WIL...
Read More
BioCentury | Jan 7, 2016
Financial News

Accelerator launches N.Y.-based Petra with $48M

...in Cantley's lab. For now, Accelerator's management team will serve as Petra's management team. Petra wil...
Read More
BioCentury | Mar 4, 2013
Company News

Dezima board of directors update

...B.V. , Naarden, the Netherlands Business: Cardiovascular Appointed: Marco Boorsma, principal at Forbion Capital Partners; Wil...
Read More
BioCentury | Mar 1, 2013
Financial News

Dezima raises EUR 14.2 million

...Dutch Ministry of Economic Affairs. Forbion's Marco Boorsma, New Science Ventures' Somu Subramaniam and BioGeneration's Wil...
Read More
Items per page:
1 - 10 of 21
BioCentury | Nov 19, 2020
Finance

Syncona enters kidney disease space with gene therapy newco Purespring

...area, and Spanish start-up Ninevah Therapeutics S.L. is developing gene therapies for monogenic kidney disorders.Hollowood wil...
Read More
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

Catalent Inc. (NYSE:CTLT) said Manja Boerman will become president of cell and gene therapy, succeeding Pete Buzy, who will continue as chairman of the gene therapy business. Boerman was president of the biotech’s European biologics...
Read More
BioCentury | May 22, 2019
Company News

Management tracks: Gottlieb re-joining NEA; plus Seattle Genetics, Celsius and more

...a consultant and SAB member for the gene therapy company. Voyager said CMO Omar Khwaja wil...
Read More
BioCentury | Oct 31, 2016
Financial News

Financial tracks

...named David Spaight operating partner in its healthcare group. Spaight was chairman and CEO of WIL...
Read More
BioCentury | Sep 2, 2016
Politics & Policy

Holiday notice

...Monday, Sept. 5, in observance of the Labor Day holiday in the U.S. BioCentury Extra wil...
Read More
BioCentury | Jan 16, 2016
Politics & Policy

Holiday notice

...BioCentury Extra wil not publish Monday, Jan. 18, in observance of the Martin Luther King, Jr...
Read More
BioCentury | Jan 11, 2016
Analyst Picks & Changes

Finance

...raised his target range to $87-$90 from $78-$80 after Charles River said it will acquire WIL...
Read More
BioCentury | Jan 7, 2016
Financial News

Accelerator launches N.Y.-based Petra with $48M

...in Cantley's lab. For now, Accelerator's management team will serve as Petra's management team. Petra wil...
Read More
BioCentury | Mar 4, 2013
Company News

Dezima board of directors update

...B.V. , Naarden, the Netherlands Business: Cardiovascular Appointed: Marco Boorsma, principal at Forbion Capital Partners; Wil...
Read More
BioCentury | Mar 1, 2013
Financial News

Dezima raises EUR 14.2 million

...Dutch Ministry of Economic Affairs. Forbion's Marco Boorsma, New Science Ventures' Somu Subramaniam and BioGeneration's Wil...
Read More
Items per page:
1 - 10 of 21